Caregiver Wellness After Traumatic Brain Injury (CG-WELL): An Intervention Designed to Promote Well-being in Caregivers of Acute Moderate to Severe Traumatic Brain Injuries
Natalie Kreitzer · with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · NCT05307640
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- August 16, 2021
- Record last updated
- March 26, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
After injury, survivors of msTBI depend on informal family caregivers. Upwards of 77% of family caregivers experience poor outcomes, such as adverse life changes, poor health related quality of life, and increased depressive symptoms. Caregivers frequently report minimal support or training to prepare them for their new role. Periods of care transitions, such as ICU discharge, are most difficult. The majority (93%) of previously developed caregiver and caregiver/survivor dyad interventions after msTBI focus on providing information or practical skills to either survivors, or to long-term caregivers (>6 months post injury), rather than education, support, and skill-building that the new caregiver may use proactively that will benefit the dyad acutely after injury. The Aims of this proposal are to: (1) Determine feasibility, satisfaction, and data trends of CG-Well; and (2) Understand how baseline psychosocial risk factors affect response to CG-Well compared to an Information, Support, and Referral control group. To accomplish this, I will first enroll 6-10 caregivers and tailor CG-well until each finds the intervention acceptable, appropriate, and feasible. I will then enroll 100 (50/group) dyads and determine satisfaction ratings, recruitment, retention, and treatment fidelity of CG-Well. Additionally, I will determine if caregivers report reductions in depressive symptoms and improvements in life changes as a result of improvements in task difficulty and threat appraisal in CG-Well compared to ISR at six months. Information obtained in Aims 1 and 2 will be used to plan a larger Phase III trial of CG-Well. Completing these Aims and the training plan will improve outcomes of caregivers and downstream outcomes of survivors of msTBI, and provide me with the skillset necessary to become an independent researcher who can develop and test high-impact, high-fidelity, sustainable interventions.
Being studied: CG-Well; Information Support & Referral (ISR)
Conditions: Trauma, Brain
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Survivor and caregiver ≥18 years old
- Survivor GCS 3-12 after resuscitation
- Survivor \< 2 weeks post injury
- English Speaking - survivor and caregiver
Exclusion criteria
- Patient not expected to survive.
- Pregnant - survivor or caregiver
- Prisoner - survivor or caregiver
- History of pre-existing condition that would interfere with follow-up in caregiver or survivor (e.g., substance abuse, alcoholism, end-stage cancers)
- Major prior debilitating neurological or mental health disorder in caregiver or survivor (e.g., schizophrenia, bipolar, stroke, dementia).
Recruiting US locations
University of Cincinnati
Cincinnati, OH 45267
Site contact: Emily Werff · 513-307-2963 · werffel@ucmail.uc.edu
Study contacts (from the official record)
- Emily Werff · 513-307-2963 · werffel@ucmail.uc.edu
- Stephanie Thomas · 513-315-4001 · notlins@ucmail.uc.edu
Similar studies in Ohio
All neurology studies in Ohio →- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Cincinnati, OH + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Columbus, OH + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd.
- Location
- Beachwood, OH + 16 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Cincinnati, OH + 35 other US sites
- Eligibility basics
- Ages 18–65